Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simridarlimab in hematologic malignancies
NCT04795128Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simridarlimab in hematologic malignancy, sponsored by Innovent Biologics. Primary endpoints: Number of treatment related Adverse Events and Number of patients with response. Started May 2021; status: completed.
02
Drugs
simridarlimab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04795128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795128.